Several possible studies
Story checked
Ozempic Teeth, Muscle Loss: Some of the Buzziest GLP-1 Side Effects | MedPage Today (opens in a new tab)
medpagetoday.com · 2026-08-11
Short answer
Several possible studiesNo confirmed study match.
Several papers could fit this story, but none could be confirmed as its source. The claims remain unverified.
These papers were considered as possible sources, but none could be confirmed as the study behind this story.
Share this check
The story
Ozempic Teeth, Muscle Loss: Some of the Buzziest GLP-1 Side Effects | MedPage Today
medpagetoday.com · 2026-08-11
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 11 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/primarycare/diabetes/120583
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/meetingcoverage/endo/116481
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/popmedicine/cultureclinic/116629
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/popmedicine/cultureclinic/120936
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/endocrinology/diabetes/122311
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/ophthalmology/generalophthalmology/115919
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/endocrinology/diabetes/97895
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/surgery/anesthesiology/112821
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/endocrinology/thyroid/113915
- Cited as backgroundpresented as earlier work
https://www.medpagetoday.com/popmedicine/cultureclinic/117880
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 11Not checkedNausea, vomiting, and diarrhea are some of the most commonly reported adverse effects of GLP-1 drugs, and they have been evident since initial FDA approvals for type 2 diabetes, showing up consistently in clinical trials and systematic reviews.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 11Not checkedStudies have suggested that patients taking GLP-1 drugs can lose lean muscle mass alongside weight, and eating more protein may help offset some of that loss.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 11Not checkedPatients have reported oral health issues while taking GLP-1 agonists, including dry mouth, sensitivity, and gum inflammation; experts told MedPage Today this tends to stem from dehydration issues that the drugs can bring on.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 11Not checkedSome patients taking these drugs have reported emotional flattening involving a dulled response not just to food, but to other sources of joy as well.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 11Not checkedEarly research and clinical trial data have suggested hair loss may be a side effect of these drugs, though it may be more of a problem for women than men.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 11Not checkedThe European Medicines Agency warned of a rare but potentially severe side effect with semaglutide: non-arteritic anterior ischemic optic neuropathy (NAION), which the agency determined could affect up to 1 in 10,000 people taking the drug.View evidenceHide evidence
As statedup to 1 in 10,000 people
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 11Not checkedStudies have also shown potential relationships between GLP-1 drugs and several ophthalmic conditions, including neovascular age-related macular degeneration and diabetic retinopathy.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 8 of 11Not checkedGLP-1 agonists have been linked to some risk of gallbladder issues, including gallstones and cholecystitis, though the absolute risk is small.View evidenceHide evidence
As statedabsolute risk is small
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 9 of 11Not checkedThe FDA added a warning in 2024 about pulmonary aspiration during general anesthesia or deep sedation to most GLP-1 drugs after rare postmarketing reports in surgical patients.View evidenceHide evidence
As statedrare
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 10 of 11Not checkedThyroid C-cell tumors have long had a known association with this drug class, and some recent work has suggested the increased risk of thyroid cancer seen with GLP-1 drugs is tied to increased surveillance.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 11 of 11Not checkedGLP-1 drugs may throw off some medical scans, specifically by influencing the interpretation of cancer PET-CT scans because they could boost uptake of the tracer.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.
Search results
Candidate papers, not confirmed sources.
PubMed, Europe PMC, Crossref · 15 candidate papers
GLP-1 Receptor Agonists and Insulin Versus Insulin for Perioperative Glycemic Control in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Systematic Review.
Annals of Cardiac Anaesthesia · 2026 · PubMed, Europe PMC
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events
JAMA · 2024 · Crossref
Adverse Events Associated with Incretin-Based Therapies: A Narrative Review on Mechanisms, Clinical Management, and Risk Mitigation.
2026 · Europe PMC
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
Lancet (London, England) · 2026 · PubMed
GLP-1 Receptor Agonists and Gastrointestinal Adverse Events—Reply
JAMA · 2024 · Crossref